Current treatment of visceral leishmaniasis (Kala-azar): an overview

Premshanker S. Singh, Manoj Kumar

Abstract


Visceral Leishmaniasis (VL) is also popularly known as kala-azar which was first reported in early forties and since then it continues to affect millions of people. The ranges of common drugs available for the treatment of visceral leishmaniasis are limited. It mainly includes pentavalent antimonials e.g. stibogluconate (SbV), amphotericin B deoxycholate (AB), lipid formulations of amphotericin B (L-AB), miltefosine (MF) and paromomycin (PM) - all of which have limitations in terms of toxicity, variable efficacy, price and inconvenient treatment schedules. Most are parenteral except MF which is administered orally. Due to the parasite’s drug resistance, the most widely used (SbV) of these drugs is now of little use in northern Bihar, India, which alone accounts for 50% of the world's burden of visceral leishmaniasis. In areas of resistance to SbV, AB is highly effective. The formulation of AB in liposomes (L-AB) has been a major advancement in the treatment of visceral leishmaniasis. However, despite a significant reduction in price, this treatment remains very expensive for endemic countries like India. Combination short course therapy has been reported by many researchers who found that it is equally effective as conventional monotherapy with added benefits of less side effects, better compliance and less resistance. The aim of this article is to review the current aspects of the treatment for leishmaniasis, giving an overview of current agents clinically used to new agents & modalities of treatment under development.


Keywords


Leishmaniasis, Kala-azar, Treatment, Drugs

Full Text:

PDF

References


Van Griensven J, Diro E. Visceral leishmaniasis. Infect Dis Clin North Am. 2012;26:309-22.

Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013;14:53-63.

Berman JD. Human leishmaniasis; clinical, diagnostic and therapeutic developments in last 10 years. Clin Infect Dis. 1997;24:684-703.

Sundar S, Murray HW. Cure of SbV unresponsive Indian visceral leishmaniasis with ampho B lipid complex. J Infect Dis. 1996;173:762-5.

Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate and review of pertinent clinical studies. Am J Trop Med Hyg. 1992;46:296-306.

Sundar S, Singh VP, Sharma S, More DK, Makharia MK, Murray HW. Failure of pentavalent antimony in visceral leishmaniasisin India: report from centre of Indian epidemic. Clin Infect Dis. 2000;31:1104-7.

Peter W. The treatment of kala-azar: new approach to an old problem. Indi J Med Res. 1981;73(Suppl):1-18.

World Health Organisation. The leishmaniasis: Report of a WHO Expert Committee. WHO Tech Rep Ser 1984;701:1-140.

World Health Organisation. The control of leishmaniasis: Report of an expert committee. WHO Tech Rep Ser. 1990;793:50-5.

Thakur CP, Kumar M, Singh SK et al. Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J. 1984;288:895-7.

Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK. Rationalisation of the regimens of treatment of kala-azar with sodium stibogluconate in India: a randomized study. Br Med J. 1988;26:21-5.

Lira R, Sundar S, Makharia A et al. Evidence of the high incidence of treatment failures in Indian kala-azar is due to emergence of SbV resistant strains of Leishmania donovani. J Infect Dis. 1999;180:564-7.

Thakur CP, Sinha GP, Pandey AK et al. Do the diminishing efficacy and increasing toxicity of SbV in the treatment of visceral leishmaniasis in Bihar, justify its continued use as first line drug? Ann Trop Med Parasitol. 1998;92:561-9.

Thakur CP, Kumar M, Pandey AK. Comparison of regimens of treatment of antimony resistant kala-azar patients. Am J Trop Med Hyg. 1991;45:435-41.

Sundar S, More DK, Singh VP, Murray HW et al. Failure of SbV in visceral leishmaniasis in India. Clin Infect Dis. 2000;31:1104-7.

Thakur CP, Sinha GP, Sharma V et al. Evalaution of amphotericin B as a first line drug in comparison of SbV in the treatment of fresh cases of kala-azar. Indian J Med Res. 1993;97:170-5.

Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus SbV in first line treatment of Indian kala-azar. Lancet. 1994;344:1599-6.

Sundar S, Agrawal NK, Sinha PR, Horwith G, Murray HW. Cure with short course low/dose amphotericin B lipid complex therapy for antimony unresponsive visceral leishmaniasis. Ann Int Med. 1997;127:133-7.

Mastroianni A. Liposomal amphotericin B and rHuGM-CSF for treatment of visceral leishmaniasis in AIDS. Infez Med. 2004;12:197–204.

Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW. Amphotericin B lipid complex in the management of antimony unresponsive Indian leishmaniasis. J Assoc Physicians India. 1999;47:186-8.

Meyerhoff A. US Food and Drug Administration approval of AmBisome for treatment of visceral leishmaniasis. Clin Infect Dis. 1999;28:42-8.

Thakur CP, Pandey AK, Sinha GP et al. Comparison of three treatment regimens with AmBisome for visceral leishmaniasis in India. Trans R Soc Trop Med Hyg. 1996;90:319-22.

Sundar S, Agrawal G, Rai M, Murray HW et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B. Br Med J. 2001;323:419-22.

Thakur CP, Olliaro P, Gothoskar S et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (paromomycin) - antimonial combinations: a pilot study in Bihar, India. Trans R Soc Trop Med Hyg. 1992;86(6):615-6.

Dietze R, Milan EP, Berman JD et al. Treatment of Brazilian kala-azar with short course Amphocil amphotericin B cholesterol dispersion. Clin Infect Dis. 1993;17:981-6.

Sundar S, Gupta LB, Rasthogi V, Agrawal G, Murray HW. Short course, cost effective treatment with amphotericin B fat emulsion cures visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000;94:2000-4.

Mattock NM, Peters W. The experimental chemotherapy of leishmaniasis II. Ann Trop Med Parasitol. 1975;69:359-71.

Thakur CP, Olliero P, Gothoskar S et al. Treatment of visceral leishmaniasis with aminosidine antimonial combinations: a pilot study in Bihar. Trans R Soc Trop Med Hyg 1992;86:615-6.

Thakur CP, Bhowmick S, Dolfi L, Olliero P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar. A randomized dose finding clinical trial. Trans R Soc Trop Med Hyg. 1998;88:219-23.

Seaman J, Pryce D, Moody A et al. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate alone. J Infect Dis. 1993;168:715-20.

Jha TK, Olliaro P, Thakur CP et al. Randomised control trial of aminosidine vs. SbV for treating visceral leishmaniasis in North Bihar, India. Br Med J. 1998;316:1200-5.

Sundar S, Singh VP, Makharia MK, Murray HW. Response to interferon gamma plus SbV in Indian visceral leishmaniasis. J Infect Dis. 1997;176:1117-9.

Sunder S, Rosenkaimer F, Makharia MK et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet. 1998;352:1821-6.

Sherwood JA, Gachihi GS, Muigai RK et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis. 1994;19:1034-9.

Laguna F, Lopez-Velez R, Soriano V, Montilla P, Alvar J, Gonzalez-Lahoz JM. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect. 1994;28:255-9.

Lopez-Velez R, Videla S, Marquez M et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2004;53:540-3.

Molina I, Falco V, Crespo M et al. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2007;60:837-42.

Sunder et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011:377:477-86.

Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasisin India. N Engl J Med. 2010;362:504-12.

Salih NA et al. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease? Trop Med Int Health. 2014 Feb;19(2):146-52.

Van Griensven J et al. HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infect Dis. 2013 Mar;13(3):251-9.

Mohamed-Ahmed AH et al. Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis. Curr Opin Infect Dis. 2012 Dec;25(6):695-702.

Ejazi SA, Ali N. Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects. Expert Rev Anti Infect Ther. 2013 Jan;11(1):79-98.

Freitas-Junior LH et al. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist. 2012 Jan;2:11-9.

Moore EM et al. Treatment of visceral leishmaniasis. J Glob Infect Dis. 2010 May-Aug;2(2):151-8.

Fernandes AP et al. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. Curr Opin Microbiol. 2012 Aug;15(4):476-85.

Saljoughian N et al. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl Trop Dis. 2013 Apr;7(4):e2174

Kashino SS et al. Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates. Parasite Immunol. 2012 Jul;34(7):360-71. McCall LI et al. Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis. Vaccine. 2013 Feb 27;31(10):1420-5.

Elvidge, Suzanne. World’s first kala-azar vaccine enters the clinic, 2012. Available at FierceVaccines.com. Accessed 1 March 2012.